Alnylam Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2830 www.alnylam.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development - Mar 5th, 2026 7:05 am
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - Mar 5th, 2026 6:30 am
Is Canada’s AMVUTTRA Reimbursement Tailwind Altering The Investment Case For Alnylam Pharmaceuticals (ALNY)? - Mar 5th, 2026 1:13 am
Alnylam Reimbursement Win And Trial Progress Versus Current Valuation Signals - Mar 4th, 2026 4:19 pm
Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight - Mar 4th, 2026 4:01 pm
Blackstone puts $400M into Teva, Sanofi gut disease drug - Mar 4th, 2026 4:57 am
Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors - Mar 3rd, 2026 7:00 am
Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf. - Mar 2nd, 2026 9:39 pm
Alnylam Receives Positive Recommendation From Canada's Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (vutrisiran injection), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis - Mar 2nd, 2026 6:01 am
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Mar 2nd, 2026 2:05 am
Canaccord Genuity Maintains Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY) Stock - Feb 28th, 2026 11:33 pm
Does Alnylam Pharmaceuticals (ALNY) Price Reflect Its RNAi Pipeline Potential? - Feb 27th, 2026 9:26 pm
GSK Strikes $1 Billion China RNA Deal - Feb 24th, 2026 9:43 am
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference - Feb 23rd, 2026 8:00 am
Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge - Feb 20th, 2026 2:08 am
Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth - Feb 18th, 2026 10:01 pm
Assessing Alnylam Pharmaceuticals (ALNY) Valuation As Mixed Share Price Returns Meet Bullish Fair Value Models - Feb 18th, 2026 2:15 am
Why Alnylam Pharmaceuticals Stock Was Soaring on Monday - Feb 17th, 2026 1:47 pm
RNA-targeting small molecules: a new frontier of drug discovery - Feb 17th, 2026 10:09 am
Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? - Feb 13th, 2026 11:21 pm